Evidence map›Paper›PMID 21689436›Full record

ArticleMalaria journal2011

Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.

Daniel Dodoo, Michael R Hollingdale, Dorothy Anum, Kwadwo A Koram, Ben Gyan, Bartholomew D Akanmori, Josephine Ocran, Susan Adu-Amankwah, Harini Geneshan, Esteban Abot and 10 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. IdentifyingResearch square · 2024
    Article
  6. Article
  7. Article
  8. Importance of the Immunodominant CD8Infection and immunity · 2020
    Article
  9. Article
  10. Immune Signature AgainstMolecular & cellular proteomics : MCP · 2020
    Article
  11. Article
  12. Article
  13. Comprehensive Review of HumanFrontiers in immunology · 2019
    Review
  14. Synthetic Antigens Derived fromThe American journal of tropical medicine and hygiene · 2017
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 5 countries.

Daniel DodooNoguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
Michael R Hollingdale
Dorothy Anum
Kwadwo A Koram
Ben Gyan
Bartholomew D Akanmori
Josephine Ocran
Susan Adu-Amankwah
Harini Geneshan
Esteban Abot
Jennylyn Legano
Glenna Banania
Renato Sayo
Donald Brambilla
Sanjai Kumar
Denise L Doolan
William O Rogers
Judith Epstein
Thomas L Richie
Martha Sedegah
Naval Medical Research Command · USNoguchi Memorial Institute for Medical Research · GHUniversity of Ghana · GHCenter for Biologics Evaluation and Research · USQIMR Berghofer Medical Research Institute · AU

Funding

MALARIA--ENDEMIC AREA CLIN RESEARCH &TRIAL PREP SITE-266995363N01AI095363 · NIAID · UNIVERSITY OF GHANA · 1999 to 2004
–
NIAID NIH HHS N01 AI95363
6 · The paper itself

Abstract

backgroundTo prepare field sites for malaria vaccine trials, it is important to determine baseline antibody and T cell responses to candidate malaria vaccine antigens. Assessing T cell responses is especially challenging, given genetic restriction, low responses observed in endemic areas, their variability over time, potential suppression by parasitaemia and the intrinsic variability of the assays.

methodsIn Part A of this study, antibody titres were measured in adults from urban and rural communities in Ghana to recombinant Plasmodium falciparum CSP, SSP2/TRAP, LSA1, EXP1, MSP1, MSP3 and EBA175 by ELISA, and to sporozoites and infected erythrocytes by IFA. Positive ELISA responses were determined using two methods. T cell responses to defined CD8 or CD4 T cell epitopes from CSP, SSP2/TRAP, LSA1 and EXP1 were measured by ex vivo IFN-γ ELISpot assays using HLA-matched Class I- and DR-restricted synthetic peptides. In Part B, the reproducibility of the ELISpot assay to CSP and AMA1 was measured by repeating assays of individual samples using peptide pools and low, medium or high stringency criteria for defining positive responses, and by comparing samples collected two weeks apart.

resultsIn Part A, positive antibody responses varied widely from 17%-100%, according to the antigen and statistical method, with blood stage antigens showing more frequent and higher magnitude responses. ELISA titres were higher in rural subjects, while IFA titres and the frequencies and magnitudes of ex vivo ELISpot activities were similar in both communities. DR-restricted peptides showed stronger responses than Class I-restricted peptides. In Part B, the most stringent statistical criteria gave the fewest, and the least stringent the most positive responses, with reproducibility slightly higher using the least stringent method when assays were repeated. Results varied significantly between the two-week time-points for many participants.

conclusionsAll participants were positive for at least one malaria protein by ELISA, with results dependent on the criteria for positivity. Likewise, ELISpot responses varied among participants, but were relatively reproducible by the three methods tested, especially the least stringent, when assays were repeated. However, results often differed between samples taken two weeks apart, indicating significant biological variability over short intervals.

Indexed as

AdolescentAdultAntibodies, ProtozoanAntigens, ProtozoanEnzyme-Linked Immunosorbent AssayEnzyme-Linked Immunospot AssayFemaleFluorescent Antibody Technique, IndirectGhanaHumansInterferon-gammaMalaria, FalciparumMalaria VaccinesMaleMiddle AgedPlasmodium falciparumAntibodies, ProtozoanAntigens, ProtozoanInterferon-gammaMalaria VaccinesRecombinant Proteins

Identifiers

PMID21689436
PMCPMC3132199
OpenAlexW2101431448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.